Literature DB >> 31018673

The Nonalcoholic Fatty Liver Disease Fibrosis Score Is Related to Epicardial Fat Thickness and Complexity of Coronary Artery Disease.

Yaşar Turan1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of the metabolic syndrome and is associated with cardiovascular disease (CVD). The NAFLD Fibrosis Score (NFS) is an index used for the detection of liver fibrosis. We investigated the relationship between NFS and complexity of coronary artery disease (CAD). In this cross-sectional study, 109 patients with CAD and 50 patients without CAD were enrolled. Demographic data, laboratory parameters, epicardial fat thickness (EFT), NFS, and Synergy between percutaneous coronary intervention with Taxus and cardiac surgery (SYNTAX) score were recorded. Waist circumference, fasting glucose, low-density lipoprotein cholesterol (LDL-C), EFT, and NFS were significantly higher in the CAD group (P < .05). High-density lipoprotein cholesterol (HDL-C) and ejection fraction were significantly lower in the CAD group (P < .05). The SYNTAX score was positively correlated with fasting glucose, LDL-C, EFT, and NFS and negatively correlated with HDL-C (P < .05). The NFS was positively correlated with EFT (P = .019). Multivariate linear regression analysis revealed that NFS (P = .012), EFT (P < .001), and LDL-C (P = .001) were independently associated with the SYNTAX score. In conclusion, NFS, as a marker of NAFLD, could identify patients at higher risk of CVD.

Entities:  

Keywords:  coronary artery disease; epicardial fat thickness; nonalcoholic fatty liver disease fibrosis score

Year:  2019        PMID: 31018673     DOI: 10.1177/0003319719844933

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  10 in total

1.  Association of epicardial adipose tissue with non-alcoholic fatty liver disease: a meta-analysis.

Authors:  Bin Liu; Yingrui Li; Yu Li; Yajie Liu; Yuling Yan; Aoran Luo; Hong Ren; Qiang She
Journal:  Hepatol Int       Date:  2019-08-20       Impact factor: 6.047

2.  Relationship between non-invasively detected liver fibrosis and in-hospital outcomes in patients with acute coronary syndrome undergoing PCI.

Authors:  Flavio Giuseppe Biccirè; Francesco Barillà; Emanuele Sammartini; Edoardo Maria Dacierno; Gaetano Tanzilli; Daniele Pastori
Journal:  Clin Res Cardiol       Date:  2022-08-11       Impact factor: 6.138

3.  Endothelial Dysfunction, a Marker of Atherosclerosis, Is Independent of Metabolic Syndrome in NAFLD Patients.

Authors:  Jimmy Narayan; Haribhakti Seba Das; Preetam Nath; Ayaskanta Singh; Debakanta Mishra; Pradeep Kumar Padhi; Shivaram Prasad Singh
Journal:  Int J Hepatol       Date:  2020-07-17

4.  One-Year Outcomes of Percutaneous Coronary Intervention in Patients with End-Stage Liver Disease.

Authors:  Daniel Y Lu; Matthew D Saybolt; Daniel H Kiss; William H Matthai; Kimberly A Forde; Jay Giri; Robert L Wilensky
Journal:  Clin Med Insights Cardiol       Date:  2020-01-22

5.  NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study.

Authors:  Jia Peng; Ming-Ming Liu; Jing-Lu Jin; Ye-Xuan Cao; Yuan-Lin Guo; Na-Qiong Wu; Cheng-Gang Zhu; Qian Dong; Jing Sun; Rui-Xia Xu; Jian-Jun Li
Journal:  Lipids Health Dis       Date:  2022-01-07       Impact factor: 3.876

6.  Association between Coronary Artery Plaque Progression and Liver Fibrosis Biomarkers in Population with Low Calcium Scores.

Authors:  Tsung-Ying Tsai; Pai-Feng Hsu; Cheng-Hsueh Wu; Shao-Sung Huang; Wan-Leong Chan; Shing-Jong Lin; Jaw-Wen Chen; Tse-Min Lu; Hsin-Bang Leu
Journal:  Nutrients       Date:  2022-07-30       Impact factor: 6.706

Review 7.  Ischemic Heart Disease and Liver Cirrhosis: Adding Insult to Injury.

Authors:  Irina Gîrleanu; Anca Trifan; Laura Huiban; Cristina Muzîca; Oana Cristina Petrea; Ana Maria Sîngeap; Camelia Cojocariu; Stefan Chiriac; Tudor Cuciureanu; Irina Iuliana Costache; Carol Stanciu
Journal:  Life (Basel)       Date:  2022-07-12

8.  Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease.

Authors:  Peter P Toth; Gregory G Schwartz; Stephen J Nicholls; Aziz Khan; Michael Szarek; Henry N Ginsberg; Jan O Johansson; Kamyar Kalantar-Zadeh; Ewelina Kulikowski; Ken Lebioda; Norman C W Wong; Michael Sweeney; Kausik K Ray
Journal:  Am J Prev Cardiol       Date:  2022-08-08

Review 9.  Epicardial Adipose Tissue: Clinical Biomarker of Cardio-Metabolic Risk.

Authors:  Alexandra C Villasante Fricke; Gianluca Iacobellis
Journal:  Int J Mol Sci       Date:  2019-11-28       Impact factor: 5.923

Review 10.  The association between epicardial adipose tissue and non-alcoholic fatty liver disease: A systematic review of existing human studies.

Authors:  Hadi Emamat; Hadith Tangestani; Mojgan Behrad Nasab; Hamid Ghalandari; Azita Hekmatdoost
Journal:  EXCLI J       Date:  2021-06-14       Impact factor: 4.068

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.